|Bid||0.0000 x 21500|
|Ask||0.0000 x 36900|
|Day's Range||1.1800 - 1.2400|
|52 Week Range||0.2000 - 4.3000|
|Beta (5Y Monthly)||0.43|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 07, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
DURHAM, NC / ACCESSWIRE / September 9, 2020 / Heat Biologics, Inc.
Superior pre-clinical activity compared to conventional costimulatory antibody combination administered systemicallyDURHAM, NC / ACCESSWIRE / September 2, 2020 / Heat Biologics, Inc.
COVID-19 vaccine stocks have easily been the hottest niche across the entire market since March. Developmental-stage companies like Inovio Pharmaceuticals (NASDAQ: INO), Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), Vaxart (NASDAQ: VXRT), and Heat Biologics (NASDAQ: HTBX) all saw their shares rise at a dizzying pace in 2020, thanks to their coronavirus vaccine candidates.